vs
C4 Therapeutics, Inc.（CCCC）与Laird Superfood, Inc.（LSF）财务数据对比。点击上方公司名可切换其他公司
Laird Superfood, Inc.的季度营收约是C4 Therapeutics, Inc.的1.2倍（$13.3M vs $11.0M），Laird Superfood, Inc.净利率更高（-13.2% vs -186.0%，领先172.8%），C4 Therapeutics, Inc.同比增速更快（112.8% vs 15.0%），过去两年C4 Therapeutics, Inc.的营收复合增速更高（90.4% vs 16.1%）
C4 Therapeutics是一家临床阶段生物制药企业，专注于开发靶向蛋白降解疗法，用于治疗癌症及其他存在重大未满足医疗需求的严重疾病。公司依托自有专利TORPEDO平台设计小分子降解剂清除致病蛋白，目前拥有多条肿瘤领域研发管线，并与头部制药企业达成战略合作。
Laird Superfood是一家主营植物基功能性超级食品的企业，产品涵盖精品咖啡奶精、补水混合饮品、营养补充剂、植物能量零食等，面向健康意识较强的消费群体，主要在北美市场通过电商及线下零售渠道销售，主打可持续采购的清洁配方。
CCCC vs LSF — 直观对比
营收规模更大
LSF
是对方的1.2倍
$11.0M
营收增速更快
CCCC
高出97.8%
15.0%
净利率更高
LSF
高出172.8%
-186.0%
两年增速更快
CCCC
近两年复合增速
16.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $11.0M | $13.3M |
| 净利润 | $-20.5M | $-1.8M |
| 毛利率 | — | 34.1% |
| 营业利润率 | -210.1% | -13.5% |
| 净利率 | -186.0% | -13.2% |
| 营收同比 | 112.8% | 15.0% |
| 净利润同比 | 40.7% | -341.4% |
| 每股收益（稀释后） | $-0.09 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCCCLSF
| Q4 25 | $11.0M | $13.3M | ||
| Q3 25 | $11.2M | $12.9M | ||
| Q2 25 | $6.5M | $12.0M | ||
| Q1 25 | $7.2M | $11.7M | ||
| Q4 24 | $5.2M | $11.6M | ||
| Q3 24 | $15.4M | $11.8M | ||
| Q2 24 | $12.0M | $10.0M | ||
| Q1 24 | $3.0M | $9.9M |
净利润CCCCLSF
| Q4 25 | $-20.5M | $-1.8M | ||
| Q3 25 | $-32.2M | $-975.1K | ||
| Q2 25 | $-26.0M | $-362.2K | ||
| Q1 25 | $-26.3M | $-156.2K | ||
| Q4 24 | $-34.6M | $-398.4K | ||
| Q3 24 | $-24.7M | $-166.1K | ||
| Q2 24 | $-17.7M | $-239.1K | ||
| Q1 24 | $-28.4M | $-1.0M |
毛利率CCCCLSF
| Q4 25 | — | 34.1% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | 39.9% | ||
| Q1 25 | — | 41.9% | ||
| Q4 24 | — | 38.6% | ||
| Q3 24 | — | 43.0% | ||
| Q2 24 | — | 41.8% | ||
| Q1 24 | — | 40.0% |
营业利润率CCCCLSF
| Q4 25 | -210.1% | -13.5% | ||
| Q3 25 | -306.4% | -7.7% | ||
| Q2 25 | -441.0% | -3.3% | ||
| Q1 25 | -402.9% | -1.9% | ||
| Q4 24 | -728.4% | -4.1% | ||
| Q3 24 | -183.9% | -2.3% | ||
| Q2 24 | -178.6% | -3.4% | ||
| Q1 24 | -1060.2% | -11.0% |
净利率CCCCLSF
| Q4 25 | -186.0% | -13.2% | ||
| Q3 25 | -286.4% | -7.6% | ||
| Q2 25 | -402.6% | -3.0% | ||
| Q1 25 | -363.7% | -1.3% | ||
| Q4 24 | -667.8% | -3.4% | ||
| Q3 24 | -160.6% | -1.4% | ||
| Q2 24 | -147.6% | -2.4% | ||
| Q1 24 | -933.2% | -10.3% |
每股收益（稀释后）CCCCLSF
| Q4 25 | $-0.09 | — | ||
| Q3 25 | $-0.44 | — | ||
| Q2 25 | $-0.37 | — | ||
| Q1 25 | $-0.37 | — | ||
| Q4 24 | $-0.50 | — | ||
| Q3 24 | $-0.35 | — | ||
| Q2 24 | $-0.26 | — | ||
| Q1 24 | $-0.41 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $74.6M | $5.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $256.6M | $11.5M |
| 总资产 | $359.1M | $19.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCCCLSF
| Q4 25 | $74.6M | $5.1M | ||
| Q3 25 | $58.8M | $5.1M | ||
| Q2 25 | $78.2M | $3.9M | ||
| Q1 25 | $51.3M | $7.0M | ||
| Q4 24 | $55.5M | $8.3M | ||
| Q3 24 | $59.6M | $7.9M | ||
| Q2 24 | $73.1M | $7.6M | ||
| Q1 24 | $89.7M | $7.1M |
股东权益CCCCLSF
| Q4 25 | $256.6M | $11.5M | ||
| Q3 25 | $154.4M | $12.8M | ||
| Q2 25 | $174.1M | $13.4M | ||
| Q1 25 | $195.1M | $13.3M | ||
| Q4 24 | $216.0M | $13.2M | ||
| Q3 24 | $242.7M | $13.1M | ||
| Q2 24 | $247.1M | $12.6M | ||
| Q1 24 | $258.3M | $12.7M |
总资产CCCCLSF
| Q4 25 | $359.1M | $19.2M | ||
| Q3 25 | $265.5M | $18.9M | ||
| Q2 25 | $296.5M | $20.4M | ||
| Q1 25 | $319.5M | $21.5M | ||
| Q4 24 | $349.6M | $19.3M | ||
| Q3 24 | $376.1M | $18.8M | ||
| Q2 24 | $381.1M | $18.0M | ||
| Q1 24 | $398.4M | $17.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.1M | $68.4K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CCCCLSF
| Q4 25 | $-22.1M | $68.4K | ||
| Q3 25 | $-31.2M | $1.2M | ||
| Q2 25 | $-12.1M | $-2.8M | ||
| Q1 25 | $-33.3M | $-1.3M | ||
| Q4 24 | $-17.9M | $339.2K | ||
| Q3 24 | $-24.1M | $305.8K | ||
| Q2 24 | $-5.0M | $642.7K | ||
| Q1 24 | $-18.1M | $-422.3K |
自由现金流CCCCLSF
| Q4 25 | — | — | ||
| Q3 25 | $-31.6M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-17.9M | — | ||
| Q3 24 | $-24.1M | — | ||
| Q2 24 | $-5.2M | — | ||
| Q1 24 | — | — |
自由现金流率CCCCLSF
| Q4 25 | — | — | ||
| Q3 25 | -281.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -346.5% | — | ||
| Q3 24 | -157.2% | — | ||
| Q2 24 | -43.1% | — | ||
| Q1 24 | — | — |
资本支出强度CCCCLSF
| Q4 25 | — | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 1.6% | — | ||
| Q1 24 | 0.0% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCCC
暂无分部数据
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
